Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Gains from Sales and Divestitures (2021 - 2025)

Oramed Pharmaceuticals filings provide 5 years of Gains from Sales and Divestitures readings, the most recent being $1.9 million for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 103.05% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, up 103.05% year-over-year, with the annual reading at $1.9 million for FY2025, 103.05% up from the prior year.
  • Gains from Sales and Divestitures hit $1.9 million in Q4 2025 for Oramed Pharmaceuticals, up from $925937.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.9 million in Q4 2025 and bottomed at $218000.0 in Q4 2022.
  • Average Gains from Sales and Divestitures over 5 years is $756466.2, with a median of $521625.0 recorded in 2023.
  • The largest annual shift saw Gains from Sales and Divestitures surged 139.28% in 2023 before it soared 77.51% in 2024.
  • Oramed Pharmaceuticals' Gains from Sales and Divestitures stood at $236665.0 in 2021, then fell by 7.89% to $218000.0 in 2022, then soared by 139.28% to $521625.0 in 2023, then soared by 77.51% to $925937.0 in 2024, then soared by 103.05% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Gains from Sales and Divestitures are $1.9 million (Q4 2025), $925937.0 (Q4 2024), and $521625.0 (Q4 2023).